Digital Self-Care could ease lymphatic pain after breast cancer

NCT ID NCT07701018

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests a digital behavioral program called The-Optimal-Lymph-Flow (TOLF Self-Care) for breast cancer survivors who experience lymphatic pain—a common, often painful condition that can lead to chronic lymphedema. The program teaches self-care skills to promote lymph flow, aiming to reduce pain, swelling, and improve daily living. Researchers will implement the digital assessment and intervention in a clinical setting with 35 participants to see if it helps manage symptoms and prevent progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
The-Optimal-Lymph-Flow (TOLF Self-Care), a non-pharmacological digital behavioral intervention that teaches self-care skills to promote lymph flow and reduce pain and swelling.
What this could lead to
If effective, this digital self-care program could offer a simple, non-drug way to reduce lymphatic pain and prevent lymphedema from becoming chronic in breast cancer survivors.
What could go wrong
This is a small, early-stage adaptation study with only 35 participants, so results may not apply to all patients. The intervention relies on patient self-report and self-care, which may vary in effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Missouri-Kansas City

    Kansas City, Missouri, 64108, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.